NGGT has initiated Phase I/II clinical trials in the U.S. and China to evaluate the safety and efficacy of NGGT002 for the <a ta ...

The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...

The Philippine Health Insurance Corporation (PhilHealth) endorsed five 'better benefit packages' for heart attacks, rare ...

(“Next Generation Gene Therapeutics” or “NGGT”), a clinical-stage biotechnology company pioneering the next wave of gene therapy innovation for genetic rare diseases, today announced positive new data ...

The Philippine Health Insurance Corporation (PhilHealth) endorsed new enhanced benefit packages to the agency’s board. The ...

Q3 2024 Earnings Call Transcript November 7, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.39, ...

THE Benefits Committee (BenCom) of the Philippine Health Insurance Corporation (PhilHealth) Board of Directors endorsed on Friday to the board en banc better benefit packages for heart attacks, 10 ...

including Maple Syrup Urine Disease, Methylmalonic Acidemia/Propionic Acidemia, Galactosemia, Phenylketonuria, Gaucher ...

Argentina has documented over 1,200 cases of inborn metabolic disorders annually, with phenylketonuria being the most ...

Scientists at Pennington Biomedical Research Center, along with a colleague from Peking University People's Hospital in China ...

Dr. Hu is professor and director of the Chronic Disease Epidemiology Laboratory, and Dr. Shen is assistant professor-research in chronic disease epidemiology at Pennington Biomedical. Dr. Zou is ...